COMMUNIQUÉS West-GlobeNewswire

Kuros Biosciences increases 2026 annual guidance, The company reports 40% year-over-year increase in sales in the first nine months of 2026
15/10/2026
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases 2026 annual guidance The company reports 40% year-over-year increase in sales in the first nine months of 2026 Schlieren ( [...]
IBA sélectionnée pour équiper l’expansion aux États-Unis d’un leader de la production de radiopharmaceutiques avec une commande de 12 systèmes Cyclone® KIUBE
15/10/2026
IBA devient le fournisseur privilégié pour équiper de 12 systèmes un réseau national de production de radiopharmaceutiques TEP, sécurisant des capacités de production en anticipation de la demande dans les domaines du [...]
IBA selected to support the US expansion of a leading radiopharmaceutical producer with an order for 12 Cyclone® KIUBE systems
15/10/2026
IBA is preferred supplier for a 12-system national PET radiopharmaceutical production network, securing capacity ahead of demand across diagnostics and theranostics Louvain-la-Neuve, Belgium – October 15, 2026, 7 a.m [...]
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
15/10/2026
October 15, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, [...]
OSE Immunotherapeutics présentera lors de la 10ème Chardan Annual Healthcare Conference
15/10/2026
Nantes, France, 15 octobre 2026 – 7h30 CEST – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnémo: OSE) , une société de biotechnologie au stade clinique développant des thérapies first-in-class en immuno-oncologie [...]
OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare Conference
15/10/2026
Nantes, France, October 15, 2026 – 7:30am CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and [...]
OMass Therapeutics Announces $310 Million Series C Financing to Advance Portfolio of Small Molecule Therapeutics in Endocrinology and Immunology
15/10/2026
Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with strong participation from additional new and existing investors Proceeds to advance MC2 receptor antagonist OMS1620 through [...]
Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue
15/10/2026
Preliminary Q3 2026 revenue expected to range from $10.1 million to $10.4 million Expected quarter-over-quarter growth of approximately 11% to 14% compared with Q2 2026 Expected year-over-year growth of approximately 15 [...]
EC-Council Releases ADG 2.0 and Offers Its AI Governance Crosswalks Free to Every Government, Regulator and Standards Body as Nations Split on AI Rules
15/10/2026
With autonomous no global treaty in sight, EC-Council will assist any public authority that asks to map ADG 2.0's 180+ controls to its own laws and standards Photo Courtesy of EC-Council TAMPA, Fla., Oct. 14, 2026 ( [...]
Golden Touch Fusion CBD Gummies: Official Product Information for Adults as the Federal Hemp Definition Changes November 12, 2026
14/10/2026
Total THC definition, 0.4 mg per-container limit, FDA-identified CBD gummies side effects, medication and pregnancy guidance, and customer care explained. El Cajon, CA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- These statements [...]
EmblemHealth Maintains 4-Star Medicare Rating, Highlighting Sustained Quality Performance
14/10/2026
EmblemHealth’s largest Medicare Advantage contract achieved a 4-star rating for the second consecutive year amid a national landscape where only 37% of comparable plans reached that threshold. NEW YORK, Oct. 14, 2026 ( [...]
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
14/10/2026
If approved, tinlarebant would be the first-ever approved treatment for Stargardt Disease Type 1 in Singapore, United Kingdom, and Switzerland Access pathway submission combined with accepted new drug applications in [...]
Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics
14/10/2026
Previously announced wind-down of the legacy cell therapy activities is substantially complete Mechelen, Belgium; October 14, 2026, 22.01 CEST; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced [...]
MannKind to Participate in the Chardan Healthcare Conference
14/10/2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , today announced that Chief Executive Officer Michael Castagna will participate in a panel focused on [...]
MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026
14/10/2026
MARIETTA, Ga., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended [...]
Teladoc Health to Announce Third Quarter 2026 Financial Results
14/10/2026
NEW YORK, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release third quarter 2026 results on Wednesday, October 28, 2026, after the market [...]
Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026
14/10/2026
SEATTLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
14/10/2026
Topline results expected mid-December 2026 REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating [...]
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
14/10/2026
Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- [...]

Pages